AR058567A1 - Formulaciones de proteinas estables - Google Patents
Formulaciones de proteinas establesInfo
- Publication number
- AR058567A1 AR058567A1 ARP060105626A ARP060105626A AR058567A1 AR 058567 A1 AR058567 A1 AR 058567A1 AR P060105626 A ARP060105626 A AR P060105626A AR P060105626 A ARP060105626 A AR P060105626A AR 058567 A1 AR058567 A1 AR 058567A1
- Authority
- AR
- Argentina
- Prior art keywords
- ctla4lg
- routes
- formulations
- formulation
- molecules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 4
- 238000007920 subcutaneous administration Methods 0.000 abstract 3
- 238000001990 intravenous administration Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000024664 tolerance induction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Formulaciones estables que comprenden las moléculas de CTLA4lg, molécula de proteína que comprende al menos un polipéptico que tiene un dominio extracelular de CTLA4lg o porcion del mismo y una region constante de inmunoglobulina o porcion del mismo, incluyendo las formulaciones liofilizadas y líquidas para la asministracion por medio de diversas rutas incluyendo, por ejemplo, rutas tales como las rutas intravenosa (IV) y subcutánea (SC) para tratar enfermedades del sistema inmune e induccion de tolerancia. Reivindicacion 1: Una formulacion estable, adecuada para la administracion subcutánea, caracterizada porque comprende al menos 100 mg/ml de moléculas de CTLA4lg, un azucar capaz de estabilizar la formulacion a una concentracion efectiva para la misma, y un portador acuoso farmacéuticamente aceptable. Reivindicacion 7: La formulacion de conformidad con la reivincicacion 1, caracterizada porque la molécula de CTLA4lg tiene la secuencia de aminoácidos mostrada en la SEQ ID NO:2 comenzando con la metionina en la posicion 27 o alanina en la posicion 26 y terminando en la lisina en la posicion 383 o glisina en la posicion 382.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75215005P | 2005-12-20 | 2005-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058567A1 true AR058567A1 (es) | 2008-02-13 |
Family
ID=38057529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105626A AR058567A1 (es) | 2005-12-20 | 2006-12-19 | Formulaciones de proteinas estables |
| ARP140103315A AR097561A2 (es) | 2005-12-20 | 2014-09-04 | Un método para la obtención de una composición que comprende una población aislada de moléculas del antígeno 4 de linfocito t citotóxico ligado a la región constante de cadena pesada de inmunoglobulina (ctla-ig) a partir de un medio de cultivo líquido |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103315A AR097561A2 (es) | 2005-12-20 | 2014-09-04 | Un método para la obtención de una composición que comprende una población aislada de moléculas del antígeno 4 de linfocito t citotóxico ligado a la región constante de cadena pesada de inmunoglobulina (ctla-ig) a partir de un medio de cultivo líquido |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8476239B2 (es) |
| EP (1) | EP1962886B2 (es) |
| JP (2) | JP5247467B2 (es) |
| KR (1) | KR101378194B1 (es) |
| CN (3) | CN101584858A (es) |
| AR (2) | AR058567A1 (es) |
| AU (1) | AU2006330593B2 (es) |
| BR (1) | BRPI0622256A2 (es) |
| CA (1) | CA2634547C (es) |
| CL (1) | CL2010000816A1 (es) |
| DK (1) | DK1962886T4 (es) |
| EA (1) | EA014232B1 (es) |
| ES (1) | ES2436616T5 (es) |
| HR (1) | HRP20131196T4 (es) |
| IL (1) | IL192104A (es) |
| NO (1) | NO347247B1 (es) |
| NZ (1) | NZ569108A (es) |
| PE (1) | PE20071063A1 (es) |
| PL (1) | PL1962886T6 (es) |
| PT (1) | PT1962886E (es) |
| RS (1) | RS53127B2 (es) |
| SG (1) | SG153832A1 (es) |
| TW (3) | TW200738261A (es) |
| WO (1) | WO2007076354A2 (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| CA2634547C (en) * | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| TWI423986B (zh) | 2005-12-20 | 2014-01-21 | 必治妥美雅史谷比公司 | 組合物及製造組合物之方法 |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| EP2345433B1 (en) | 2008-10-06 | 2017-03-01 | 3-D Matrix, Ltd. | Tissue plug |
| US9216388B2 (en) * | 2009-06-23 | 2015-12-22 | Ge Healthcare Bio-Sciences Ab | Simulator device |
| GB201009676D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
| US20140147418A1 (en) * | 2011-04-15 | 2014-05-29 | The Us Of America, As Represented By The Secretary Department Of Health And Human Services | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome |
| WO2012145523A2 (en) | 2011-04-20 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| JP6117191B2 (ja) | 2011-10-07 | 2017-04-19 | 武田薬品工業株式会社 | 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物 |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| BR112014009031A2 (pt) | 2011-10-18 | 2017-05-09 | Coherus Biosciences Inc | formulações de etanercept estabilizadas com íons de metais |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| ES2753150T3 (es) | 2012-06-29 | 2020-04-07 | Bristol Myers Squibb Co | Métodos para reducir la agregación de glucoproteínas |
| JP6389170B2 (ja) * | 2012-07-06 | 2018-09-12 | スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． | ペプチド溶液のためのフィル−フィニッシュ過程 |
| MX2015000337A (es) * | 2012-07-09 | 2015-09-25 | Coherus Biosciences Inc | Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. |
| ES2729561T3 (es) | 2012-08-31 | 2019-11-04 | Us Health | Transferencia del gen acuaporina mediada por un virus adenoasociado (aav) para el tratamiento del síndrome de Sjögren |
| MX2015003007A (es) | 2012-09-07 | 2015-06-05 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab. |
| LT2895188T (lt) | 2012-09-11 | 2018-04-10 | Coherus Biosciences, Inc. | Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas |
| WO2014149067A1 (en) * | 2013-03-15 | 2014-09-25 | Momenta Pharmaceuticals, Inc. | Methods related to ctla4-fc fusion proteins |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| CN103385852B (zh) * | 2013-08-06 | 2015-03-11 | 南京正大天晴制药有限公司 | 一种盐酸法舒地尔注射液及其制备方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
| CA2939696C (en) | 2014-03-10 | 2023-01-10 | 3-D Matrix, Ltd. | Self-assembling peptide compositions |
| JP6684719B2 (ja) | 2014-03-10 | 2020-04-22 | 株式会社スリー・ディー・マトリックス | ペプチド組成物の滅菌および濾過 |
| KR20160124912A (ko) | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
| US11058768B2 (en) * | 2014-04-16 | 2021-07-13 | Biocon Ltd. | Stable protein formulations comprising a molar excess of sorbitol |
| KR20160145789A (ko) | 2014-04-25 | 2016-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도 |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| EP3157942B1 (en) | 2014-06-23 | 2020-06-17 | Novartis AG | Site specific protein modifications |
| WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| WO2016080367A1 (ja) | 2014-11-18 | 2016-05-26 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| JP6883569B2 (ja) * | 2015-09-11 | 2021-06-09 | ダウ グローバル テクノロジーズ エルエルシー | タンパク質及びポリアルコキシ脂肪族化合物を含む組成物 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| PL3386541T3 (pl) | 2015-12-07 | 2021-04-06 | Merck Patent Gmbh | Wodna formulacja farmaceutyczna zawierającą przeciwciało anty-pd-1 awelumab |
| WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| EP3630843A2 (en) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| CN108014338A (zh) * | 2018-01-22 | 2018-05-11 | 安徽未名生物医药有限公司 | 一种注射用巴利昔单抗冻干粉针及其制备方法 |
| EP3801606A1 (en) * | 2018-05-25 | 2021-04-14 | Dr. Reddy's Laboratories Ltd. | Ctla4-ig fusion protein formulation |
| JP7449243B2 (ja) * | 2018-05-25 | 2024-03-13 | ドクター レディズ ラボラトリーズ リミテッド | 安定な融合タンパク質製剤 |
| US20210338586A1 (en) * | 2018-06-26 | 2021-11-04 | Lupin Limited | Stable lyophilized dosage form of protein |
| CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| JP2022513626A (ja) | 2018-11-26 | 2022-02-09 | ノバルティス アーゲー | Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド |
| JP7645185B2 (ja) | 2019-01-15 | 2025-03-13 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
| WO2020152367A1 (en) | 2019-01-25 | 2020-07-30 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
| BR112022012064A2 (pt) * | 2019-12-20 | 2022-08-30 | Anthos Therapeutics Inc | Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico |
| GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
| GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
| WO2022162704A1 (en) * | 2021-02-01 | 2022-08-04 | Dr. Reddy's Laboratories Limited | Compositions comprising fusion protein and analytical attributes thereof |
| BR112023019385A2 (pt) | 2021-03-23 | 2023-12-05 | King S College London | Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso |
| CN113925963B (zh) * | 2021-10-15 | 2023-08-11 | 江苏太平洋美诺克生物药业股份有限公司 | 一种稳定的包含抗cd147单克隆抗体的药物制剂 |
| GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
| JP2025532724A (ja) * | 2022-09-29 | 2025-10-03 | ファイザー・インク | Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物 |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| WO2025196207A1 (en) | 2024-03-20 | 2025-09-25 | King's College London | Compositions and methods for use in depleting senescent cells and treating aging |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ296649B6 (cs) * | 1993-02-23 | 2006-05-17 | Genentech, Inc. | Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu |
| DE4405426A1 (de) * | 1994-02-21 | 1995-08-24 | Boehringer Mannheim Gmbh | Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| MX9800684A (es) * | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| WO2003005465A1 (en) | 2001-04-25 | 2003-01-16 | Quallion, Llc | Rechargeable lithium battery for tolerating discharge to zero volts |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| CA2413190C (en) | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| HUP0303930A3 (en) | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| EP2322165A1 (en) | 2001-11-13 | 2011-05-18 | Genentech, Inc. | Apo2 ligand/TRAIL formulations |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| DE10204792A1 (de) | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| WO2003068259A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| KR101088223B1 (ko) | 2002-12-23 | 2011-11-30 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상 |
| BR0317723A (pt) | 2002-12-23 | 2005-11-22 | Bristol Myers Squibb Co | Processo de cultura de células de mamìfero para a produção de proteìna |
| DK1610820T4 (da) * | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| EP1670499A4 (en) | 2003-08-04 | 2009-07-22 | Bristol Myers Squibb Co | METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1916997B1 (en) * | 2005-08-05 | 2018-04-18 | Amgen Inc. | Stable aqueous protein pharmaceutical formulations and their preparation |
| CA2634547C (en) * | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
-
2006
- 2006-12-19 CA CA2634547A patent/CA2634547C/en active Active
- 2006-12-19 PE PE2006001649A patent/PE20071063A1/es active IP Right Grant
- 2006-12-19 BR BRPI0622256-0A patent/BRPI0622256A2/pt not_active Application Discontinuation
- 2006-12-19 SG SG200904148-4A patent/SG153832A1/en unknown
- 2006-12-19 NO NO20082628A patent/NO347247B1/no unknown
- 2006-12-19 AR ARP060105626A patent/AR058567A1/es not_active Application Discontinuation
- 2006-12-19 TW TW095147647A patent/TW200738261A/zh unknown
- 2006-12-19 CN CNA2009101398246A patent/CN101584858A/zh active Pending
- 2006-12-19 KR KR1020087017544A patent/KR101378194B1/ko active Active
- 2006-12-19 EP EP06846683.8A patent/EP1962886B2/en active Active
- 2006-12-19 EA EA200801570A patent/EA014232B1/ru active Protection Beyond IP Right Term
- 2006-12-19 AU AU2006330593A patent/AU2006330593B2/en active Active
- 2006-12-19 TW TW098139142A patent/TWI393575B/zh active
- 2006-12-19 JP JP2008547721A patent/JP5247467B2/ja active Active
- 2006-12-19 CN CN200910139825A patent/CN101822820A/zh active Pending
- 2006-12-19 US US12/086,876 patent/US8476239B2/en active Active
- 2006-12-19 HR HRP20131196TT patent/HRP20131196T4/hr unknown
- 2006-12-19 PL PL06846683.8T patent/PL1962886T6/pl unknown
- 2006-12-19 CN CN2006800530514A patent/CN101378773B/zh active Active
- 2006-12-19 ES ES06846683T patent/ES2436616T5/es active Active
- 2006-12-19 TW TW098139141A patent/TW201008595A/zh unknown
- 2006-12-19 NZ NZ569108A patent/NZ569108A/en unknown
- 2006-12-19 PT PT68466838T patent/PT1962886E/pt unknown
- 2006-12-19 DK DK06846683.8T patent/DK1962886T4/da active
- 2006-12-19 WO PCT/US2006/062297 patent/WO2007076354A2/en not_active Ceased
- 2006-12-20 RS RS20130553A patent/RS53127B2/sr unknown
-
2008
- 2008-06-12 IL IL192104A patent/IL192104A/en active IP Right Grant
-
2010
- 2010-07-30 CL CL2010000816A patent/CL2010000816A1/es unknown
-
2011
- 2011-06-27 JP JP2011141983A patent/JP5538309B2/ja active Active
-
2014
- 2014-09-04 AR ARP140103315A patent/AR097561A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| de Lencastre Novaes et al. | Stability, purification, and applications of bromelain: A review | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| CY1124265T1 (el) | Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| CY1111232T1 (el) | Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης | |
| UA107571C2 (xx) | Фармацевтична композиція | |
| AR092400A1 (es) | Formulaciones de anticuerpos y proteinas de alta concentracion | |
| ES2980738T3 (es) | Composición para uso en un método inmunoestimulador | |
| CA2846598A1 (en) | Treatment of degenerative joint disease | |
| EA200601169A1 (ru) | Конъюгаты иммуногенных пептидных носителей и способы их получения | |
| EP2694708A2 (en) | Formulations with reduced viscosity | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| CN113423722A (zh) | 用于胞吞转运的递送构建体及相关方法 | |
| US20230158100A1 (en) | Treatment of panx1 associates diseases | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada | |
| BRPI0406745A (pt) | Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| WO2006052821A3 (en) | Compositions and methods for treatment of protein misfolding and protein aggregation diseases | |
| US10138273B2 (en) | Peptide ligands for hepatic stellate cells | |
| RU2019113989A (ru) | Лекарственное средство | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| KR20080080079A (ko) | 샤페로닌 10에 의해 유도되는 면역조절 | |
| JP7766489B2 (ja) | 免疫調節特性を有するペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |